158 related articles for article (PubMed ID: 35059351)
1. Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?
Ramalho D; Araújo A; Rocha G; Duarte-Ribeiro F
Eur J Case Rep Intern Med; 2021; 8(12):003099. PubMed ID: 35059351
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
[TBL] [Abstract][Full Text] [Related]
3. Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
Chiloiro S; Giampietro A; Bianchi A; Menotti S; Angelini F; Tartaglione T; Antonini Cappellini GC; De Galitiis F; Rossi E; Schinzari G; Scoppola A; Pontecorvi A; De Marinis L; Fleseriu M
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983597
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
5. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
6. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
7. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.
Atkins P; Ur E
Endocr Res; 2020 Nov; 45(4):246-253. PubMed ID: 32892666
[TBL] [Abstract][Full Text] [Related]
8. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
Chodakiewitz Y; Brown S; Boxerman JL; Brody JM; Rogg JM
Clin Neurol Neurosurg; 2014 Oct; 125():125-30. PubMed ID: 25127260
[TBL] [Abstract][Full Text] [Related]
10. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
11. Clinical presentation and management of hypophysitis: An observational study of case series.
Karrou M; Benyakhlef S; Alla A; Messaoudi N; Amar AO; Rouf S; Kamaoui I; Oulali N; Moufid F; Abda N; Latrech H
Surg Neurol Int; 2021; 12():304. PubMed ID: 34345445
[TBL] [Abstract][Full Text] [Related]
12. Intracranial Germinoma Masquerading as Secondary Granulomatous Hypophysitis: A Case Report and Review of Literature.
Pal R; Rai A; Vaiphei K; Gangadhar P; Gupta P; Mukherjee KK; Singh P; Ray N; Bhansali A; Dutta P
Neuroendocrinology; 2020; 110(5):422-429. PubMed ID: 31269501
[TBL] [Abstract][Full Text] [Related]
13. Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis.
Balti E; Verhaeghe S; Kruse V; Roels S; Coremans P
Cureus; 2022 Aug; 14(8):e27763. PubMed ID: 36127991
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
15. Clinical Interrogation for Unveiling an Isolated Hypophysitis Mimicking Pituitary Adenoma.
Lee S; Choi JH; Kim CJ; Kim JH
World Neurosurg; 2017 Mar; 99():735-744. PubMed ID: 27476691
[TBL] [Abstract][Full Text] [Related]
16. New causes of hypophysitis.
Yuen KCJ; Popovic V; Trainer PJ
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101276. PubMed ID: 31078416
[TBL] [Abstract][Full Text] [Related]
17. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
[TBL] [Abstract][Full Text] [Related]
19. Differential diagnosis of pituitary enlargement.
Štěchovská K; Tůma T; Masopust V; Kosák M
Vnitr Lek; 2022; 68(1):58-63. PubMed ID: 35459348
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
